Mon, Sep 15, 2014, 9:59 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Yongye International, Inc. Message Board

  • richard_x_roe richard_x_roe May 9, 2013 8:30 AM Flag

    Is NASDAQ looking at this now?

    The financing contract in the 10K's Exhibit 10.33 is signed by ZHAO Shijun as the legal representative of Yongye's main subsidiary in China. He is also described as a Director of Yongye's main production subsidiary and as a Senior Manager, Head of Production of Yongye.

    In mid 2011, he provided expectations to the Chinese press for annual revenues of about $20 million and profit before tax of about $6 million for Yongye's main production subsidiary. Instead, for 2011 Yongye reported revenues of $390 million and PRC-based earnings before income taxes of $117 million, or about 20x his “guidance.”

    Moreover, last year he was quoted in an article distributed widely in Chinese government-sponsored news outlets that since 2009 Yongye has already produced over 15,000 tons of the “breakthrough” product Wujingao (乌金膏), with production to expand to 40,000 tons (or about 3/4 of Yongye's entire current “design” capacity of fulvic-acid based products at its main facility). The article points out the environmental pollution risk and inefficiency of Yongye's current production processes while praising the "new" Wujingao extraction method, citing an IMARSTB official and a university professor, in contrast to the previous glowing official assessment of Shengmingsu. Wujingao's benefits are also prominently featured in a lengthy section of Yongye's latest "use and efficacy" instruction manual for Shengmingsu, which makes it clear that Shengmingsu and Wujingao have been “developed” and are being “marketed” jointly.

    cont.

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
YONG
7.050.00(0.00%)Jul 3 1:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
Netflix, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT